Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Metabolism and Endocrine Disease›Iron Overload

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Iron Overload

Metabolism and Endocrine Disease · NLM MeSH · updated 2026-11-04 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (809 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Overload, Iron.

Where it fits in the MeSH classification

Broader topics
Iron Metabolism Disorders
Narrower topics
Hemochromatosis; Hemosiderosis

Research landscape

PubMed indexes 16,208 records tagged with the MeSH heading “Iron Overload” (counts retrieved 2026-10-31). 2,243 of them (13.8%) were published from 2020 onward, and the busiest period so far is through 1999 with 6,214 records.

Reviews account for 2,745 records (16.9%) and meta-analyses for 68. Randomized controlled trials number 138 (0.9%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 6,214 records; 2000-2009: 3,918 records; 2010-2019: 3,833 records; 2020 onward: 2,243 records6,214through 19993,9182000-20093,8332010-20192,2432020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19996,214
2000-20093,918
2010-20193,833
2020 onward2,243
Share of records by publication typeReviews: 16.9 percent; Meta-analyses: 0.4 percent; Randomized controlled trials: 0.9 percentReviews16.9% (2,745)Meta-analyses0.4% (68)Randomized controlled trials0.9% (138)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 16,208 PubMed records
TypeRecordsShare
Reviews2,74516.9%
Meta-analyses680.4%
Randomized controlled trials1380.9%

Method: PubMed query "Iron Overload"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in metabolism and endocrine disease

Studies of diabetes, obesity and hormone disorders often follow blood tests such as glucose, HbA1c or hormone levels, which are stand-ins for outcomes that matter more, such as complications. Lifestyle and diet research is largely observational, and weight and diabetes trials can differ in how long people were followed. Nothing on this page is advice about medicines, insulin or diet; talk to a qualified clinician about your own situation. Check whether the outcome was a lab value or a clinical event, and the type and duration of the condition studied.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Oxidative stress induces mitochondrial iron overload and ferroptotic cell death
Chen Y, Guo X, Zeng Y, Mo X, Hong S, He H, et al.
2023Research article
Design not recorded in structured metadata
168cc by
PMID 37726294 · DOI · PMC10509277
Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancer
Bi G, Liang J, Bian Y, Shan G, Huang Y, Lu T, et al.
2024Research article
Design not recorded in structured metadata
136cc by
PMID 38504107 · DOI · PMC10951362
Mechanisms and regulations of ferroptosis
Zhang XD, Liu ZY, Wang MS, Guo YX, Wang XK, Luo K, et al.
2023Review article
Design not recorded in structured metadata
114cc by
PMID 37868994 · DOI · PMC10587589
Iron overload in the tumor microenvironment induces CD8+ T cell ferroptosis and dysfunction
Lin Z, Lin Z, Chen H, Ke Y, Xiao H, Li C, et al.
2026Research article
Design not recorded in structured metadata
4cc by
PMID 42173913 · DOI · PMC13385831

Oxidative stress induces mitochondrial iron overload and ferroptotic cell death [1]

Research article Chen Y, Guo X, Zeng Y, Mo X, Hong S, He H, et al. · · 2023 · cited 168 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Oxidative stress has been shown to induce cell death in a wide range of human diseases including cardiac ischemia/reperfusion injury, drug induced cardiotoxicity, and heart failure.
Closing excerpt
Our results also reveal mitochondrial iron overload via HO-1 mitochondrial translocation as a key mechanism as well as a potential molecular target for oxidative stress-induced ferroptosis in cardiomyocytes.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (270 words)

Oxidative stress has been shown to induce cell death in a wide range of human diseases including cardiac ischemia/reperfusion injury, drug induced cardiotoxicity, and heart failure. However, the mechanism of cell death induced by oxidative stress remains incompletely understood. Here we provide new evidence that oxidative stress primarily induces ferroptosis, but not apoptosis, necroptosis, or mitochondria-mediated necrosis, in cardiomyocytes. Intriguingly, oxidative stress induced by organic oxidants such as tert-butyl hydroperoxide (tBHP) and cumene hydroperoxide (CHP), but not hydrogen peroxide (H2O2), promoted glutathione depletion and glutathione peroxidase 4 (GPX4) degradation in cardiomyocytes, leading to increased lipid peroxidation. Moreover, elevated oxidative stress is also linked to labile iron overload through downregulation of the transcription suppressor BTB and CNC homology 1 (Bach1), upregulation of heme oxygenase 1 (HO-1) expression, and enhanced iron release via heme degradation. Strikingly, oxidative stress also promoted HO-1 translocation to mitochondria, leading to mitochondrial iron overload and lipid reactive oxygen species (ROS) accumulation. Targeted inhibition of mitochondrial iron overload or ROS accumulation, by overexpressing mitochondrial ferritin (FTMT) or mitochondrial catalase (mCAT), respectively, markedly inhibited oxidative stress-induced ferroptosis. The levels of mitochondrial iron and lipid peroxides were also markedly increased in cardiomyocytes subjected to simulated ischemia and reperfusion (sI/R) or the chemotherapeutic agent doxorubicin (DOX). Overexpressing FTMT or mCAT effectively prevented cardiomyocyte death induced by sI/R or DOX. Taken together, oxidative stress induced by organic oxidants but not H2O2 primarily triggers ferroptotic cell death in cardiomyocyte through GPX4 and Bach1/HO-1 dependent mechanisms. Our results also reveal mitochondrial iron overload via HO-1 mitochondrial translocation as a key mechanism as well as a potential molecular target for oxidative stress-induced ferroptosis in cardiomyocytes.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37726294 · DOI · PMC10509277

Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancer [2]

Research article Bi G, Liang J, Bian Y, Shan G, Huang Y, Lu T, et al. · · 2024 · cited 136 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Targeting ferroptosis, an iron-dependent form of regulated cell death triggered by the lethal overload of lipid peroxides, in cancer therapy is impeded by our limited understanding of the intersection of tumour's metabolic feature and ferroptosis vulnerability.
Closing excerpt
Considering that cancer cells are often characterized by elevated intracellular polyamine pools, our results indicate that polyamine metabolism exposes a targetable vulnerability to ferroptosis and represents an exciting opportunity for therapeutic strategies for cancer.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (196 words)

Targeting ferroptosis, an iron-dependent form of regulated cell death triggered by the lethal overload of lipid peroxides, in cancer therapy is impeded by our limited understanding of the intersection of tumour's metabolic feature and ferroptosis vulnerability. In the present study, arginine is identified as a ferroptotic promoter using a metabolites library. This effect is mainly achieved through arginine's conversion to polyamines, which exerts their potent ferroptosis-promoting property in an H2O2-dependent manner. Notably, the expression of ornithine decarboxylase 1 (ODC1), the critical enzyme catalysing polyamine synthesis, is significantly activated by the ferroptosis signal--iron overload--through WNT/MYC signalling, as well as the subsequent elevated polyamine synthesis, thus forming a ferroptosis-iron overload-WNT/MYC-ODC1-polyamine-H2O2 positive feedback loop that amplifies ferroptosis. Meanwhile, we notice that ferroptotic cells release enhanced polyamine-containing extracellular vesicles into the microenvironment, thereby further sensitizing neighbouring cells to ferroptosis and accelerating the "spread" of ferroptosis in the tumour region. Besides, polyamine supplementation also sensitizes cancer cells or xenograft tumours to radiotherapy or chemotherapy through inducing ferroptosis. Considering that cancer cells are often characterized by elevated intracellular polyamine pools, our results indicate that polyamine metabolism exposes a targetable vulnerability to ferroptosis and represents an exciting opportunity for therapeutic strategies for cancer.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38504107 · DOI · PMC10951362

Mechanisms and regulations of ferroptosis [3]

Review article Zhang XD, Liu ZY, Wang MS, Guo YX, Wang XK, Luo K, et al. · · 2023 · cited 114 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Regulation of cell mortality for disease treatment has been the focus of research.
Closing excerpt
Here, we reviewed the researches on the mechanism of ferroptosis in recent years, and comprehensively analyzed the mechanism and regulatory process of ferroptosis from iron metabolism and lipid metabolism, and then described in detail the metabolism of GPX4 and the main non-enzymatic antioxidant GSH in vivo.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (173 words)

Regulation of cell mortality for disease treatment has been the focus of research. Ferroptosis is an iron-dependent regulated cell death whose mechanism has been extensively studied since its discovery. A large number of studies have shown that regulation of ferroptosis brings new strategies for the treatment of various benign and malignant diseases. Iron excess and lipid peroxidation are its primary metabolic features. Therefore, genes involved in iron metabolism and lipid metabolism can regulate iron overload and lipid peroxidation through direct or indirect pathways, thereby regulating ferroptosis. In addition, glutathione (GSH) is the body's primary non-enzymatic antioxidants and plays a pivotal role in the struggle against lipid peroxidation. GSH functions as an auxiliary substance for glutathione peroxidase 4 (GPX4) to convert toxic lipid peroxides to their corresponding alcohols. Here, we reviewed the researches on the mechanism of ferroptosis in recent years, and comprehensively analyzed the mechanism and regulatory process of ferroptosis from iron metabolism and lipid metabolism, and then described in detail the metabolism of GPX4 and the main non-enzymatic antioxidant GSH in vivo.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37868994 · DOI · PMC10587589

Iron overload in the tumor microenvironment induces CD8+ T cell ferroptosis and dysfunction [4]

Research article Lin Z, Lin Z, Chen H, Ke Y, Xiao H, Li C, et al. · · 2026 · cited 4 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
While iron homeostasis in cancer cells is well-established, its role in mediating crosstalk between tumors and CD8+ T cells within the tumor microenvironment (TME) remains largely elusive.
Closing excerpt
These engineered cells resist ferroptosis induced by the TME and elicit potent anti-tumor immunity.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (170 words)

While iron homeostasis in cancer cells is well-established, its role in mediating crosstalk between tumors and CD8+ T cells within the tumor microenvironment (TME) remains largely elusive. In this study, we compare iron levels across primary tissues populated by CD8+ T cells. Contrary to the systemic iron deficiency commonly found in cancer patients, the TME exhibits marked iron enrichment compared to lymphatic fluid and peripheral blood, a phenomenon primarily attributed to tumor necrosis. However, this iron-overloaded TME is detrimental to CD8+ T cells, triggering their ferroptosis and dysfunction. Mechanistically, tumoral T cell receptor (TCR) hyperactivation and tumor-derived hepcidin cooperatively downregulate the iron exporter SLC40A1 in CD8+ T cells, leading to intracellular iron accumulation and ferroptosis. Both genetic restoration of SLC40A1 and iron chelation inhibit CD8+ T cell ferroptosis and restore their cytotoxic activity, thereby suppressing tumor growth. Finally, to enhance chimeric antigen receptor T (CAR-T) cell adaptability to the iron-overloaded TME, we engineer SLC40A1-overexpressing CAR-T cells. These engineered cells resist ferroptosis induced by the TME and elicit potent anti-tumor immunity.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42173913 · DOI · PMC13385831

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Iron metabolism and iron disorders revisited in the hepcidin era [5]
    Camaschella C, Nai A, Silvestri L · Haematologica · 2020 · cited 530 times (Europe PMC)
  • Research article Iron and Cancer [6]
    Torti SV, Manz DH, Paul BT, Blanchette-Farra N, Torti FM · Annu Rev Nutr · 2018 · cited 347 times (Europe PMC)
  • Research article Hepcidin and Iron in Health and Disease [7]
    Nemeth E, Ganz T · Annu Rev Med · 2023 · cited 341 times (Europe PMC)
  • Research article Haemochromatosis [8]
    Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loréal O · Nat Rev Dis Primers · 2018 · cited 297 times (Europe PMC)
  • Research article Iron and liver fibrosis: Mechanistic and clinical aspects [9]
    Mehta KJ, Farnaud SJ, Sharp PA · World J Gastroenterol · 2019 · cited 227 times (Europe PMC)
  • Research article Iron metabolism: pathophysiology and pharmacology [10]
    Roemhild K, von Maltzahn F, Weiskirchen R, Knüchel R, von Stillfried S, Lammers T · Trends Pharmacol Sci · 2021 · cited 220 times (Europe PMC)

References

  1. Chen Y, Guo X, Zeng Y, Mo X, Hong S, He H, et al.. Oxidative stress induces mitochondrial iron overload and ferroptotic cell death. . 2023. PMID 37726294 · DOI · PMC10509277
  2. Bi G, Liang J, Bian Y, Shan G, Huang Y, Lu T, et al.. Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancer. . 2024. PMID 38504107 · DOI · PMC10951362
  3. Zhang XD, Liu ZY, Wang MS, Guo YX, Wang XK, Luo K, et al.. Mechanisms and regulations of ferroptosis. . 2023. PMID 37868994 · DOI · PMC10587589
  4. Lin Z, Lin Z, Chen H, Ke Y, Xiao H, Li C, et al.. Iron overload in the tumor microenvironment induces CD8+ T cell ferroptosis and dysfunction. . 2026. PMID 42173913 · DOI · PMC13385831
  5. Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020. PMID 31949017 · DOI · PMC7012465
  6. Torti SV, Manz DH, Paul BT, Blanchette-Farra N, Torti FM. Iron and Cancer. Annu Rev Nutr. 2018. PMID 30130469 · DOI · PMC8118195
  7. Nemeth E, Ganz T. Hepcidin and Iron in Health and Disease. Annu Rev Med. 2023. PMID 35905974 · DOI · PMC9943683
  8. Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loréal O. Haemochromatosis. Nat Rev Dis Primers. 2018. PMID 29620054 · DOI · PMC7775623
  9. Mehta KJ, Farnaud SJ, Sharp PA. Iron and liver fibrosis: Mechanistic and clinical aspects. World J Gastroenterol. 2019. PMID 30774269 · DOI · PMC6371002
  10. Roemhild K, von Maltzahn F, Weiskirchen R, Knüchel R, von Stillfried S, Lammers T. Iron metabolism: pathophysiology and pharmacology. Trends Pharmacol Sci. 2021. PMID 34090703 · DOI · PMC7611894

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-11-04; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-11-04.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • HemosiderosisMetabolism and Endocrine Disease
  • HemochromatosisRare and Inherited Diseases
  • Transfusion ReactionImmunology
  • AcidosisMetabolism and Endocrine Disease
  • Addison DiseaseMetabolism and Endocrine Disease
  • Adrenal InsufficiencyMetabolism and Endocrine Disease

All 77 articles in Metabolism and Endocrine Disease →

At a glance

16,208
PubMed records on this heading
14%
published since 2020
2,745
review articles
138
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • HemosiderosisMetabolism and Endocrine Disease
  • HemochromatosisRare and Inherited Diseases
  • Transfusion ReactionImmunology
  • AcidosisMetabolism and Endocrine Disease
  • Addison DiseaseMetabolism and Endocrine Disease

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support